156 related articles for article (PubMed ID: 6347278)
1. Adjuvant chemotherapy with cyclophosphamide or CMF in premenopausal women with stage II breast cancer.
Brincker H; Mouridsen HT; Andersen KW
Breast Cancer Res Treat; 1983; 3(1):91-5. PubMed ID: 6347278
[TBL] [Abstract][Full Text] [Related]
2. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial.
Overgaard M; Hansen PS; Overgaard J; Rose C; Andersson M; Bach F; Kjaer M; Gadeberg CC; Mouridsen HT; Jensen MB; Zedeler K
N Engl J Med; 1997 Oct; 337(14):949-55. PubMed ID: 9395428
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant therapy of premenopausal and menopausal high-risk breast cancer patients. Present status of the Danish Breast Cancer Cooperative Group Trials 77-B and 82-B.
Dombernowsky P; Brincker H; Hansen M; Mouridsen HT; Overgaard M; Panduro J; Rose C; Axelsson CK; Andersen J; Andersen KW
Acta Oncol; 1988; 27(6A):691-7. PubMed ID: 3064774
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant chemotherapy in operable breast cancer: cyclophosphamide, methotrexate, and fluorouracil versus chlorambucil, methotrexate, and fluorouracil--11-year results of Swiss Group for Clinical Cancer Research trial SAKK 27/82.
Senn HJ; Maibach R; Castiglione M; Jungi WF; Cavalli F; Leyvraz S; Obrecht JP; Schildknecht O; Siegenthaler P
J Clin Oncol; 1997 Jul; 15(7):2502-9. PubMed ID: 9215818
[TBL] [Abstract][Full Text] [Related]
5. Postmastectomy radiotherapy and concomitant adjuvant chemotherapy versus adjuvant chemotherapy alone in premenopausal breast cancer patients with positive axillary nodes.
Micheletti E; La Face B; Huscher A; Catalano G; Ambrosi E; Marini G; Simoncini E
Tumori; 1998; 84(6):652-8. PubMed ID: 10080670
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant doxorubicin and cyclophosphamide versus cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy in premenopausal women with axillary lymph node positive breast carcinoma.
Bang SM; Heo DS; Lee KH; Byun JH; Chang HM; Noh DY; Choe KJ; Bang YJ; Kim SR; Kim NK
Cancer; 2000 Dec; 89(12):2521-6. PubMed ID: 11135211
[TBL] [Abstract][Full Text] [Related]
7. Postmastectomy adjuvant chemotherapy with or without radiation therapy in women with operable breast cancer and positive axillary lymph nodes: the Southeastern Cancer Study Group experience.
Velez-Garcia E; Moore M; Vogel CL; Marcial V; Ketcham A; Bartolucci A; Liu C; Smalley R
Breast Cancer Res Treat; 1983; 3 Suppl():S49-60. PubMed ID: 6367861
[TBL] [Abstract][Full Text] [Related]
8. Concurrent cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy and radiotherapy for breast carcinoma: a well tolerated adjuvant regimen.
Isaac N; Panzarella T; Lau A; Mayers C; Kirkbride P; Tannock IF; Vallis KA
Cancer; 2002 Aug; 95(4):696-703. PubMed ID: 12209711
[TBL] [Abstract][Full Text] [Related]
9. Adriamycin, vincristine, cyclophosphamide and 5-fluorouracil (AVCF) compared with cyclophosphamide, methotrexate and 5-fluorouracil (CMF) in premenopausal breast carcinoma. Personal results.
Mathé G; Misset JL; Plagne R; Reizenstein P; Belpomme D; Le Mevel B; Guerrin J; Fumoleau P; Metz R; Delgado M
Drugs Exp Clin Res; 1986; 12(1-3):143-5. PubMed ID: 3525068
[TBL] [Abstract][Full Text] [Related]
10. Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group.
Levine MN; Bramwell VH; Pritchard KI; Norris BD; Shepherd LE; Abu-Zahra H; Findlay B; Warr D; Bowman D; Myles J; Arnold A; Vandenberg T; MacKenzie R; Robert J; Ottaway J; Burnell M; Williams CK; Tu D
J Clin Oncol; 1998 Aug; 16(8):2651-8. PubMed ID: 9704715
[TBL] [Abstract][Full Text] [Related]
11. Effect of c-erbB(2) and estrogen receptor status on survival of women with primary breast cancer treated with adjuvant cyclophosphamide/methotrexate/fluorouracil.
Miles DW; Harris WH; Gillett CE; Smith P; Barnes DM
Int J Cancer; 1999 Aug; 84(4):354-9. PubMed ID: 10404085
[TBL] [Abstract][Full Text] [Related]
12. Sequential methotrexate and fluorouracil for the treatment of node-negative breast cancer patients with estrogen receptor-negative tumors: eight-year results from National Surgical Adjuvant Breast and Bowel Project (NSABP) B-13 and first report of findings from NSABP B-19 comparing methotrexate and fluorouracil with conventional cyclophosphamide, methotrexate, and fluorouracil.
Fisher B; Dignam J; Mamounas EP; Costantino JP; Wickerham DL; Redmond C; Wolmark N; Dimitrov NV; Bowman DM; Glass AG; Atkins JN; Abramson N; Sutherland CM; Aron BS; Margolese RG
J Clin Oncol; 1996 Jul; 14(7):1982-92. PubMed ID: 8683228
[TBL] [Abstract][Full Text] [Related]
13. Evidence of a castration-mediated effect of adjuvant cytotoxic chemotherapy in premenopausal breast cancer.
Brincker H; Rose C; Rank F; Mouridsen HT; Jakobsen A; Dombernowsky P; Panduro J; Andersen KW
J Clin Oncol; 1987 Nov; 5(11):1771-8. PubMed ID: 3316514
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant cyclophosphamide, methotrexate, and fluorouracil versus fluorouracil, epirubicin, and cyclophosphamide chemotherapy in premenopausal women with axillary node-positive operable breast cancer: results of a randomized trial. The International Collaborative Cancer Group.
Coombes RC; Bliss JM; Wils J; Morvan F; Espié M; Amadori D; Gambrosier P; Richards M; Aapro M; Villar-Grimalt A; McArdle C; Pérez-López FR; Vassilopoulos P; Ferreira EP; Chilvers CE; Coombes G; Woods EM; Marty M
J Clin Oncol; 1996 Jan; 14(1):35-45. PubMed ID: 8558217
[TBL] [Abstract][Full Text] [Related]
15. Randomized trial comparing cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) with rotational CMF, epirubicin and vincristine as primary chemotherapy in operable breast carcinoma.
Cocconi G; Di Blasio B; Boni C; Bisagni G; Ceci G; Rondini E; Bella M; Leonardi F; Savoldi L; Camisa R; Bruzzi P
Cancer; 2002 Jul; 95(2):228-35. PubMed ID: 12124820
[TBL] [Abstract][Full Text] [Related]
16. The effect of postoperative radiotherapy on the feasibility of optimal dose adjuvant CMF chemotherapy in stage II breast carcinoma.
Sulkes A; Brufman G; Rizel S; Weshler Z; Biran S; Fuks Z
Int J Radiat Oncol Biol Phys; 1983 Jan; 9(1):17-21. PubMed ID: 6687724
[No Abstract] [Full Text] [Related]
17. The CMF program for operable breast cancer with positive axillary nodes. Updated analysis on the disease-free interval, site of relapse and drug tolerance.
Bonadonna G; Rossi A; Valagussa P; Banfi A; Veronesi U
Cancer; 1977 Jun; 39(6 Suppl):2904-15. PubMed ID: 326384
[TBL] [Abstract][Full Text] [Related]
18. Comparison of adjuvant chemotherapy with methotrexate and fluorouracil with and without cyclophosphamide in breast cancer patients with one to three positive axillary lymph nodes.
Shapiro CL; Gelman RS; Hayes DF; Osteen R; Obando A; Canellos GP; Frei E; Henderson IC
J Natl Cancer Inst; 1993 May; 85(10):812-7. PubMed ID: 8487326
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant chemohormonal therapy with cyclophosphamide, methotrexate, 5-fluorouracil, and prednisone (CMFP) or CMFP plus tamoxifen compared with CMF for premenopausal breast cancer patients. An Eastern Cooperative Oncology Group trial.
Tormey DC; Gray R; Gilchrist K; Grage T; Carbone PP; Wolter J; Woll JE; Cummings FJ
Cancer; 1990 Jan; 65(2):200-6. PubMed ID: 2403834
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant treatment of node-positive breast cancer with cyclophosphamide, doxorubicin, fluorouracil, and vincristine versus cyclophosphamide, methotrexate, and fluorouracil: final report after a 16-year median follow-up duration.
Misset JL; di Palma M; Delgado M; Plagne R; Chollet P; Fumoleau P; Le Mevel B; Belpomme D; Guerrin J; Fargeot P; Metz R; Ithzaki M; Hill C; Mathé G
J Clin Oncol; 1996 Apr; 14(4):1136-45. PubMed ID: 8648368
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]